DrugPatentWatch Database PreviewSee Plans and Pricing
« Back to Dashboard
The generic ingredient in VOTRIENT is pazopanib hydrochloride. There are five drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the pazopanib hydrochloride profile page.
Generic Entry Opportunity Date for 022465
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Suppliers and Packaging for NDA: 022465
Profile for product number 001
|Active Rx/OTC/Discontinued:||RX||Dosage:||TABLET;ORAL||Strength||EQ 200MG BASE|
|Approval Date:||Oct 19, 2009||TE:||RLD:||Yes|
|Regulatory Exclusivity Expiration:||Apr 26, 2019|
|Regulatory Exclusivity Use:||ADVANCED SOFT TISSUE SARCOMA (STS) WHO HAVE RECEIVED PRIOR CHEMOTHERAPY|
|Patent:||Start Trial||Patent Expiration:||Oct 19, 2023||Product Flag?||Y||Substance Flag?||Y||Delist Request?|
|Patent:||Start Trial||Patent Expiration:||Dec 19, 2021||Product Flag?||Y||Substance Flag?||Y||Delist Request?|
Complete Access Available with Subscription